Benign multiple sclerosis: A distinct clinical entity with therapeutic implications

Current Topics in Microbiology and Immunology

Volumn 318, Issue , 2008, Pages 1-17

  Pittock, S J ^a,b   Rodriguez, M ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PARACETAMOL; MONOCLONAL ANTIBODY; PEPTIDE;

ALOPECIA; AMENORRHEA; ANXIETY; ARTHROPATHY; BENIGN MULTIPLE SCLEROSIS; BLOOD TOXICITY; CARDIOMYOPATHY; CHEST TIGHTNESS; CLINICAL TRIAL; DEPRESSION; DISABILITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED MEDICINE; EYE COLOR; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEART PALPITATION; HUMAN; INFECTION RISK; INFERTILITY; INJECTION SITE REACTION; LEUKEMIA; LEUKOPENIA; LIPOARTHROPATHY; LIVER FUNCTION; LOW BIRTH WEIGHT; LYMPHADENOPATHY; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; NAUSEA; NEUROIMAGING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RISK BENEFIT ANALYSIS; SCLERA COLOR; SIDE EFFECT; SPONTANEOUS ABORTION; STILLBIRTH; TERATOGENICITY; TREATMENT OUTCOME; URINE COLOR; BRAIN; PATHOPHYSIOLOGY; RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; BRAIN; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MITOXANTRONE; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 39549107778     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-73677-6_1     Document Type: Review

References (71)

1. The IFBN multiple sclerosis study group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
2. European study group in interferon beta-1b in secondary progressive MS (1998) placebo-controlled multicentre randomised trail of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497
3. Amato M, Ponziani G (2000) A prospective study on the prognosis of multiple sclerosis. Neurol Sci 21:831-838
4. Bauer H, Firnhaber W, Winkler W (1965) Prognostic criteria in multiple sclerosis. Ann N Y Acad Sci 122:542-551
5. Brass S, Narayanan S, Antel J, Lapierre Y, Collins L, Arnold D (2004) Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score. Can J Neurol Sci 31:225-228
6. Charcot J (1872) Leçons sur les maladies du système nerveux faites à La Salpetière. In: Delahaye A, Lecrosnier E (eds) Progres Medicale, Paris
7. Cohen J, Cutter G, Fischer J, Goodman A, Heidenreich F, Kooijmans M, Sandrock A, Rudick R, Simon J, Simonian N, Tsao E, Whitaker J, IMPACT Investigators. (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59:679-686
8. Confavreux C, Aimard D, Devic M (1980) Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients. Brain 103:281-300
9. Confavreux C, Compston A (2005) The natural history of multiple sclerosis. In: Compston A, Confavreaux C, Lassmann H, McDonald I, Miller D, Noseworthy J et al., (eds) Mcalpine's multiple sclerosis, 4th edn. Churchill Livingston, Philadelphia, pp 183-272
10. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 126:770-782
11. Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430-1438
12. Davie C, Silver N, Barker G, Tofts P, Thompson AJ, McDonald W, Miller D (1999) Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry 67:710-715
13. De Stefano N, Battaglini M, Stromillo ML, Zipoli V, Bartolozzi ML, Guidi L, Siracusa G, Portaccio E, Giorgio A, Sorbi S, Federico A, Amato MP (2006) Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain 129:2008-2016
14. Eriksson M, Andersen O, Runmarker B (2003) Long-term follow-up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 9:260-274
15. Falini A, Calabrese G, Filippi M, Origgi D, Lipari S, Colombo B, Comi G, Scotti G (1998) Benign versus secondary-progressive multiple sclerosis: The potential role of proton MR spectroscopy in defining the nature of disability. ANJR Am J Neuroradiol 19:223-229
16. Filippi M, Campi A, Mammi S, Martinelli V, Locatelli T, Scotti G, Amadio S, Canal N, Comi G (1995) Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 58:31-37
17. Filippi M, Campi A, Mammi S, Sacares P, MacManus D, Thompson A, Tofts P, McDonald W, Miller D (1994) Benign and secondary progressive multiple sclerosis: A preliminary quantitative MRI study. J Neurol 241:246-251
18. Filippi M, Inglese M, Rovaris M, Sormani M, Horsfield M, Iannucci P, Colombo B, Comi G (2000) Magnetization transfer imaging to monitor the evolution of MS: A 1-year follow-up study. Neurology 55:940-946
19. Fog T, Linnemann F (1970) The course of multiple sclerosis in 73 cases with computer-designed curves. Acta Neurol Scand 46:1-175
20. Francis G (2004) Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 251:V42-V49
21. Frohman E, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief M, Stuve O, Racke M, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M (2006) Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 63:614-619
22. Goodkin D, Hertsgaard D (2000) Seasonal variation of multiple sclerosis exacerbations in North Dakota. Arch Neurol 46:1015-1018
23. Hartung H, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey S, Krapf H, Zwingers T (2002) Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018-2025
24. Hawkins S, McDonnella G (1999) Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 67:148-152
25. Horsfield M, Lai M, Webb S, Barker G, Tofts P, Turner R, Rudge P, Miller D (1996) Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. Magn Reson Med 36:393-400
26. Johnson K, Brooks B, Cohen J, Ford C, Goldstein J, Lisak R, Myers L, Panitch H, Rose J, Schiffer R, Vollmer T, Weiner L, Wolinsky J (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276
27. Johnson K, Brooks B, Ford C, Goodman A, Guarnaccia J, Lisak R, Myers L, Panitch H, Pruitt A, Rose J, Kachuck N, Wolinsky J (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 multiple sclerosis study group. Mult Scler 6:255-266
28. Kantarci O, De Andrade M, Weinshenker B (2002) Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 123:144-159
29. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, Turan F, Ozmenoglu M, Togrul E, Demirkiran M (1998) Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 51:765-772
30. Kappos L, Clanet M, Sandberg-Wollheim M, Radue E, Hartung H, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S (2005) Neutralizing antibodies and efficacy of interferon beta-1a: A 4-year controlled study. Neurology 65:40-47
31. Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, Kingsley DP, Moseley IF, du Boulay EP, McDonald WI (1990) Heterogeneity of blood-brain barrier changes in multiple sclerosis: An MRI study with gadolinium-DTPA enhancement. Neurology 40:229-235
32. Kinkel R (2006) Im interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66:678-684
33. Koopman R, Li D, Grochowsky E, Cutler P, Paty D (1989) Benign versus chronic progressive multiple sclerosis: Magnetic resonance imaging features. Ann Neurol 25:74-81
34. Kurtzke J (1977) Geography in multiple sclerosis. J Neurol 215:1-26
35. Kurtzke J (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444-1452
36. Kurtzke J, Beebe G, Nagler B, Auth T, Kurland L, Nefzger M (1968) Studies on natural history of multiple sclerosis. 4: Clinical features of the onset bout. Acta Neurol Scand 44:467-499
37. Kurtzke J, Beebe G, Nagler B, Nefzger M, Auth T, Kurland L (1970) Studies on the natural history of multiple sclerosis 5: Long-term survival in young men. Arch Neurol 22:215-225
38. Langer-Gould A, Popat R, Huang S, Cobb K, Fontoura P, Gould M (2006) Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis. Arch Neurol 63:1686-1691
39. Leibowitz U, Alter M (1970) Clinical factors associated with increased disability in multiple sclerosis. Acta Neurol Scand 46:53-70
40. Leibowitz U, Alter M (1973) Multiple sclerosis: Clues to its cause. Amsterdam: North Holland
41. Li D, Zhao G, Paty D, University of British Columbia MS/MRI Analysis Research Group, SPECTRIMS Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 56:1505-1513
42. Lublin F, Reingold S (1996) The national multiple sclerosis society USA advisory committee on clinical trails of new agents in multiple sclerosis. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46:907-911
43. McAlpine D (1964) The benign form of multiple sclerosis: Results of a long-term study. BMJ 2:1029-1032
44. McAlpine D, Compston N (1952) Some aspects of the natural history of disseminated sclerosis. Q J Med 21:135-167
45. Minneboo A, Uitdehaag B, Ader H, Barkhof F, Polman C, Castelijins J (2005) Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology 65:56-61
46. Myhr K, Riise T, Vedeler C, Nortvedt MW, Gronning R, Midgard R, Nyland HI (2001) Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 7:59-65
47. Noseworthy J, Miller D, Compston A (2005) Disease-modifying treatments in multiple sclerosis. Churchill Livingston, London, pp 729-802
48. Patzold U, Pocklington P (1982) Course of multiple sclerosis: Results of a prospective study carried out of 102 MS patients from 1976-1980. Acta Neurol Scand 65:248-266
49. Pittock S (2007) Does benign MS today imply benign MS tomorrow? Implications for treatment. Neurology 68:480-481
50. Pittock S, Mayr W, McClelland R, Jorgensen N, Weigand S, Noseworthy J, Rodriguez M (2004) Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 62:601-606
51. Pittock S, Mayr W, McClelland R, Jorgensen N, Weigand S, Noseworthy J, Weinshenker B, Rodriguez M (2004) Change in MS-related disability in a population-based cohort: A 10-year follow-up study. Neurology 62:51-59
52. Pittock S, McClelland R, Mayr W, Jorgensen N, Weinshenker B, Noseworthy J, Rodriguez M (2004) Clinical implications of benign multiple sclerosis: A 20-year population-based followup study. Ann Neurol 56:303-306
53. Pittock S, Noseworthy J, Rodriguez M (2007) MRI findings in benign multiple sclerosis are variable. J Neurol 254:539-541
54. Pittock S, Weinshenker B, Noseworthy J, Lucchinetti C, Keegan M, Wingerchuk D, Carter J, Shuster E, Rodriguez M (2006) Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 63:611-614
55. Polman C, O'Connor P, Havrdova E, Hutchinson M, Kappos L, Miller D, Phillips J, Lublin F, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara M, Sandrock A (2006) A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
56. Ramsaransing G, De Keyser J (2006) Benign course in multiple sclerosis: A review. Acta Neurol Scand 113:359-369
57. Rodriguez M, Siva A, Cross S, Stolp-Smith K, O'Brien P, Kurland L (1994) Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted county, Minnesota. Neurology 44:28-33
58. Runmarker B, Andersen O (1993) Prognostic factors in multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116:117-134
59. Sayao A, Devonshire V, Tremlett H (2007) Longitudinal follow-up of 'benign' multiple sclerosis at 20 years. Neurology 68:480-481
60. SPECTRIMS Study Group HR (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive ms: Clinical results. Neurology 56:1496-1504
61. Thompson A (1999) Benign multiple sclerosis. J Neurol Neurosurg Psychiatry 67:138
62. Thompson A, Kermode A, MacManus D, Kendall BE, Kingsley DP, Moseley IF, McDonald WI (1990) Patterns of disease activity in multiple sclerosis: Clinical and magnetic resonance imaging study. BMJ 300:631-634
63. Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, Kendall B, Feinstein A, Mcdonald WI (1992) Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 42:60-62
64. Traboulsee A, Dehmeshki J, Peters K, Griffin C, Brex P, Silver N, Ciccarrelli O, Chard D, Barker G, Thompson A, Miller D (2003) Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler 9:566-573
65. Tremlett H, Paty D, Devonshire V (2005) Disability progression in multiple sclerosis is slower than previously reported. Neurology 66:172-177
66. van Waesberghe J, Walderveen M, Castelijins J, Scheltens P, Nijeholt G, Polman C, Barkof F (1998) Patterns of lesion development in multiple sclerosis: Longitudinal observations with t1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 19:675-683
67. Weinshenker B, Bass B, Rice G (1989a) The natural history of multiple sclerosis: A geographically based study. 1. Clinical course and disability. Brain 112:133-146
68. Weinshenker B, Bass B, Rice G, Noseworthy J, Carriere W, Baskerville J, Ebers G (1989b) The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 112:133-146
69. Weinshenker B, Rice G, Noseworthy J, Carriere W, Baskerville J, Ebers G (1991) The natural history of multiple sclerosis: A geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 114:1045-1056
70. Wingerchuk D (2006) Multiple sclerosis disease-modifying therapies: Adverse effect surveillance and management. Expert Rev Neurotherapeutics 6:333-346
71. Yousry T, Major E, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue E, Jager H, Clifford D (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924-933